The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B‐cell lymphoma
- 8 May 2008
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 142 (1) , 65-68
- https://doi.org/10.1111/j.1365-2141.2008.07145.x
Abstract
T cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3zeta receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19(+) B-cell malignancies.Keywords
This publication has 15 references indexed in Scilit:
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006
- Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell ReceptorsJournal of Immunotherapy, 2006
- Killing of non‐Hodgkin lymphoma cells by autologous CD19 engineered T cellsBritish Journal of Haematology, 2005
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- Retroviral Vectors for High-Level Transgene Expression in T LymphocytesHuman Gene Therapy, 2003
- Primary Polyclonal Human T Lymphocytes Targeted to Carcino-Embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3ζ-Based Chimeric Immune ReceptorsJournal of Immunotherapy, 2002
- Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategyGene Therapy, 2001
- CD34 Splice Variant: An Attractive Marker for Selection of Gene-Modified CellsMolecular Therapy, 2000
- Natural history of HLA expression during tumour developmentImmunology Today, 1993
- Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.The Journal of Experimental Medicine, 1981